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Activating mutations in Gαq/11 are a major driver of uveal
melanoma (UM), the most common intraocular cancer in
adults. While progress has recently been made in targeting
Gαq/11 for UM therapy, the crucial role for these proteins in
normal physiology and their high structural similarity with
many other important GTPase proteins renders this approach
challenging. The aim of the current study was to validate
whether a key regulator of Gq signaling, regulator of G protein
signaling 2 (RGS2), can inhibit Gαq-mediated UM cell growth.
We used two UM cell lines, 92.1 and Mel-202, which both
contain the most common activating mutation GαqQ209L and
developed stable cell lines with doxycycline-inducible RGS2
protein expression. Using cell viability assays, we showed that
RGS2 could inhibit cell growth in both of these UM cell lines.
We also found that this effect was independent of the canonical
GTPase-activating protein activity of RGS2 but was dependent
on the association between RGS2 and Gαq. Furthermore, RGS2
induction resulted in only partial reduction in cell growth as
compared to siRNA-mediated Gαq knockdown, perhaps
because RGS2 was only able to reduce mitogen-activated protein kinase signaling downstream of phospholipase Cβ, while
leaving activation of the Hippo signaling mediators yesassociated protein 1/TAZ, the other major pathway downstream of Gαq, unaffected. Taken together, our data indicate
that RGS2 can inhibit UM cancer cell growth by associating
with GαqQ209L as a partial effector antagonist.

Uveal melanoma (UM) is the most common primary
intraocular cancer in adults, arising from melanocytes residing
within the three parts of the uveal (iris, ciliary body, and
choroid) (1). The disease is associated with a high mortality
rate, with up to 50% of patients developing metastases with a
1-year survival rate of 15% (2). There are currently no targeted
therapies for UM, and patients are limited to relying on surgery and radiation therapy, which cause severe side effects (1).
Hence, in recent years, several groups have dedicated signiﬁcant effort to identifying targeted UM therapeutic strategies.
A majority of UM patients (85%–91%) have a mutation in
either the GNAQ or GNA11 gene in a mutually exclusive
pattern (3, 4). These genes encode two members of the Gq
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subfamily of heterotrimeric G protein α subunits, Gαq and
Gα11, respectively. These proteins share 90% protein sequence
similarity and have been suggested to play similar physiological
functions (5). Mutations associated with UM all occur at either
glutamine 209 (Q209) or arginine 183 (R183) (3) and render
Gαq/11 constitutively active. This, in turn, results in constitutive activation of multiple downstream effectors, such as
mitogen-activated protein kinase (MAPK) and yes-associated
protein 1 (YAP), that contributes to accelerate abnormal cell
growth (6–10). Therefore, these oncogenic mutants have been
suggested as promising UM therapeutic targets. Recent studies
determined that Gαq/11 inhibitors, such as FR900359, show
great promise in targeting both primary and metastatic UM
tumors (11, 12). However, given the central role for Gαq/11 in
physiology, directly targeting these proteins represents a
challenge. Indeed, decreasing Gαq/11 activity by more than
50%, as demonstrated by early gene dosage studies in mice, is
likely to be lethal (13). Therefore, therapies that modulate,
rather than completely abolish, Gαq/11 activity represent a
desirable avenue. In addition to its physiological importance,
high structure similarity between Gαq/11 and other important
GTPase proteins adds another layer of complexity for selective
targeting (14).
As an alternative to targeting Gαq/11 directly, identifying
critical regulators of Gαq/11 may represent a promising, yet
underexplored, approach. One of these is represented by
regulator of G protein signaling 2 (RGS2), a member of the
RGS protein superfamily, which serve as key negative regulators of G protein–mediated signal transduction (15–17). RGS2
is unique among the more than 20 known RGS proteins, in
that it is a potent and selective regulator of Gαq/11 over other
Gα subtypes (18). RGS2 is known to deactivate Gq/11 signaling
through two distinct mechanisms (18–21). Through its canonical GTPase-activating protein (GAP) activity, RGS2 accelerates GTP hydrolysis at active Gαq/11, resulting in
diminished downstream signaling. Additionally, RGS2 can act
as an effector antagonist, binding active Gαq/11 and interrupts
interactions with its downstream effectors (22). The most
prevalent mutation in UM cells is the constitutively active
Gαq/11Q209L, representing approximately 50% of UM cases
(23). The constitutive activity for this mutant is achieved by
greatly diminishing its intrinsic GTPase activity, thus RGS2
(or any other RGS protein) cannot deactivate this mutant
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through its canonical GAP activity (22). However, RGS2 can
still act as an effector antagonist at this, and other constitutively active Gαq/11 mutants in vitro (22, 24). Therefore, we
propose that targeting RGS2 is a rational, yet unexplored
approach to reduce the functional abundance of oncogenic
Gαq/11 mutants and inhibit UM tumor growth. To this end, we
used UM cells, which endogenously express GαqQ209L (25), in
the current study, as a model system to determine the effects
of RGS2 on Gαq-dependent UM cell growth.

Results
RGS2 can suppress Gαq-dependent UM cell growth
To determine whether RGS2 can suppress Gαq-dependent
UM cell growth, we used the UM cell line 92.1, that endogenously expresses the constitutively active GαqQ209L mutant, as
a model system. We ﬁrst developed a stable cell line with
doxycycline (Dox)-inducible RGS2 expression using the LentiTet-One expression system (Clontech). Treatment of these
cells with 1 μg/ml Dox induced expression of RGS2-HA after
24 h, which was sustained for at least 72 h (Fig. 1A). We then
performed cell growth assays using the RealTime-Glo MT Cell
Viability Assay (Promega). This nonlytic assay has the beneﬁt
of enabling multiple viability measures over time, thus
enabling one well to be measured at every time point, reducing
variability. We used cells stably transduced with the empty
vector (vector ctrl) as a negative control. In the vector ctrl cells,
Dox had no signiﬁcant effect on cell growth. However, we
observed a signiﬁcant reduction of cell growth in cells with
induced RGS2-HA expression (Fig. 1D), both as compared to
the same cells without Dox, as well as to the vector control
cells in the presence of Dox. Cell number was signiﬁcantly
reduced at all time points (24, 48, and 72 h), indicating that
increased RGS2 expression can reduce growth of 92.1 UM
cells. We used an additional UM cell line, Mel-202, which also
expresses GαqQ209L as the oncogenic driver and created stable,
Dox-inducible RGS2 protein expression in these cells as well.
Similar to 92.1 cells, induction of RGS2-HA expression was
induced by 1 μg/ml Dox at 24 h and remained stable for at
least 72 h posttreatment (Fig. 1B). The induction of RGS2-HA
expression resulted in a signiﬁcant decrease in Mel-202 cell
growth at all time points (24, 48, and 72 h), as measured by the
RealTime-Glo MT Cell Viability Assay (Fig. 1E). In contrast,
induction of RGS2-HA expression resulted in no suppression
of cell growth in the breast cancer cell line MCF-7 (Fig. 1, C
and F), which is not dependent on mutations in Gαq as the
oncogenic driver. As stated above, the chosen assay paradigm
has the beneﬁt of enabling the same well being measured at
every time point; however, the reagent is only stable in cell
culture for 72 h. To make sure that the effect of RGS2-HA
induction on UM cell growth will not be compensated easily
and quickly over time, we used an end-point approach, where
cells were plated at equal cell densities on day 0, harvested on
day 2, 4, and 6, respectively, and then subjected to the
RealTime-Glo MT Cell Viability Assay. Dox was added every
2 days to maintain RGS2-HA induction. Using this approach,
we found that the suppression of cell growth induced by
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RGS2-HA was maintained at least up to 6 days in both 92.1
(Fig. 1G) and Mel-202 (Fig. 1H) cells. Cell growth was significantly lower in both cell lines as compared to vector ctrl cells
treated with Dox, as well as RGS2-HA transduced cells in the
absence of Dox. Altogether these data suggest that RGS2 can
suppress Gq-dependent UM cell growth.
RGS2 suppression of UM cell growth is dependent on Gαq
After establishing that RGS2 can inhibit GαqQ209L-dependent UM cell growth, we next aimed to determine whether this
suppression was mediated through actions of RGS2 on Gαq.
siRNA-mediated knockdown of Gαq in our stable 92.1 cell line
resulted in an 83% reduction in Gαq protein levels, as detected
by Western blot (Fig. 2A). This resulted in a large decrease in
92.1 UM cell growth (Fig. 2B), indicating that Gαq is a major
driver of proliferation in these cells, in agreement with previous literature (25). To validate the SMART-POOL siRNA used
in these studies, we used the individual siRNA oligos. All four
individual siRNAs resulted in a signiﬁcant reduction in both
Gαq protein levels (Fig. S1, A and B) and 92.1 cell growth
(Fig. S1C), although to lesser extent than what was achieved by
the SMART-POOL siRNA. Dox-mediated induction of RGS2HA in cells transfected with a nontargeting siRNA control (ctrl
siRNA) resulted in signiﬁcant reduction in cell growth
(Fig. 2B), at a similar magnitude as we had initially observed
(Fig. 1). However, RGS2 lost the ability to reduce cell growth in
cells transfected with Gαq siRNA, indicating that RGS2 suppresses 92.1 UM cell growth through actions that are dependent on Gαq. To complement our genetic approach to inhibit
Gαq, we used YM-254890 a selective Gαq/11 inhibitor (26). In
agreement with previous studies, YM-254890 caused a significant decrease in 92.1 cell growth (Figs. 2C and S1D) (27). In
the presence of YM-254890, induction of RGS2-HA expression had no additional effect on 92.1 cell growth (Fig. 2C),
conﬁrming that RGS2 suppresses Gq-dependent UM cell
growth through a mechanism that is dependent on the presence and activity of Gαq.
RGS2 suppression of UM cell growth is mediated through
association with Gαq
We next aimed to determine the mechanism by which RGS2
suppresses GαqQ209L-mediated cell growth in 92.1 cells. Previous studies have shown that while RGS2 does not have GAP
activity toward GαqQ209L, it can still bind to this constitutively
active mutant (22, 28). To conﬁrm this, we used RGS2N149A,
which is thought to possess no GAP activity toward any Gα
subtype (29, 30). In addition, we used RGS2S179D, which has
previously been shown to have impaired binding to Gαq (31).
We ﬁrst conﬁrmed the ability for RGS2WT, RGS2N149A, and
RGS2S179D to bind GαqQ209L using proteins expressed by
in vitro transcription/translation, followed by coimmunoprecipitation (co-IP) utilizing a Glu-Glu (EE) tag on
GαqQ209L. Both RGS2WT and RGS2N149A associated with
GαqQ209L to a similar degree (Fig. 3A). In contrast, RGS2S179D
was severely deﬁcient in associating with GαqQ209L (Fig. 3A).
Next, we determined the effect of RGS2N149A and RGS2S179D
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Figure 1. Induction of RGS2 protein inhibits GαqQ209L-dependent uveal melanoma cell growth. Representative Western blot and quantiﬁcation
demonstrating reliable induction of RGS2-HA protein expression after treatment with 1 μg/ml doxycycline (Dox) in stably transduced 92.1 (A; N = 5), Mel-202
(B; N = 3), and MCF-7 (C; N = 3) cells. Expression levels remain stable from 24 h up to at least 72 h (nonsigniﬁcant (ns) using Student’s unpaired t test). Cells
transduced with the empty lentivirus vector construct (Vector) served as a negative control. Cell growth of the two GαqQ209L-dependent uveal melanoma
cell lines 92.1 (D) and Mel-202 (E) is signiﬁcantly reduced by induction of RGS2-HA protein expression, using continuous detection with Real-time Glo MT
Cell Viability Assay up to 72 h. In contrast, Dox-induced induction of RGS2-HA had no signiﬁcant effect on cell growth in the ER+ breast cancer cell line MCF7 (F). The effect of RGS2-HA induction on cell growth of both 92.1 (G) and Mel-202 (H) cells was maintained up to 6 days, using an endpoint readout assay
protocol. All data were normalized against cell growth in the absence of Dox. Data in panels D, E, G, and H are the result of ﬁve independent experiments
with ﬁve technical replicates in each. Data panel F is the result of three independent experiments with ﬁve technical replicates in each. Cell growth after
induction of RGS2-HA was compared with growth in the absence of Dox (*) and the growth in the vector control cell line in the presence of Dox (#).
*/#p < 0.05; ***/###p < 0.001; ****/####p < 0.0001 using two-way ANOVA analysis with Tukey’s post hoc test for pairwise comparisons. RGS, regulator of G
protein signaling.

on 92.1 cell growth. We created stable 92.1 cell lines with Doxinducible expression of either mutant using the same strategy
as for RGS2WT. Following induction with 1 μg/ml Dox,
RGS2N149A expressed at similar levels as RGS2WT. In contrast,
RGS2S179D was expressed at signiﬁcantly higher levels than
RGS2WT (Fig. 3B). Gαq protein levels were unchanged by induction of either RGS2 variant (Fig. 3C). We next determined
the effect of the GAP-deﬁcient RGS2N149A and the Gαq
binding-deﬁcient RGS2S179D on 92.1 cell growth. Similar to
what we had observed with RGS2WT (Figs. 1 and 3D),
RGS2N149A signiﬁcantly inhibited cell growth (Fig. 3E), indicating that RGS2 inhibits Gαq-dependent UM cell growth
through a GAP-independent mechanism. In contrast. Induction of RGS2S179D did not signiﬁcantly change 92.1 cell growth

(Fig. 3F), indicating that RGS2 suppresses UM cell growth
through a mechanism that involves binding to Gαq. The suppression of cell growth by RGS2WT and RGS2N149A were
signiﬁcantly decreased at 48 and 72 h. Altogether our data
support a model where RGS2 inhibits GαqQ209L-mediated cell
proliferation through effector antagonism, rather than through
its canonical GAP activity.
RGS2 suppresses Gαq-mediated extracellular signal-regulated
kinase 1/2 phosphorylation in Gq-dependent UM cells
We next aimed to determine which signaling pathway(s)
downstream of Gαq are affected by RGS2 protein induction.
Two main signaling pathways are associated with cell
J. Biol. Chem. (2022) 298(6) 101955
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Figure 2. RGS2-mediated suppression of uveal melanoma cell growth is dependent on Gαq. A, representative Western blot and quantiﬁcation of ﬁve
independent experiments demonstrating efﬁciency of siRNA-mediated knockdown of Gαq in 92.1 cells and Dox induction of RGS2-HA protein expression.
Knockdown efﬁciency was consistently 80%. ****p < 0.0001 using one-way ANOVA with Tukey’s post hoc test for pairwise comparisons. B, cell growth of
92.1 cells was signiﬁcantly inhibited by induction of RGS2-HA protein expression or Gαq siRNA. siRNA-mediated knockdown of Gαq caused a signiﬁcantly
greater decrease in cell growth than RGS2 protein induction. In addition, the effect of RGS2 on cell growth was lost when Gαq was concurrently knocked
down. Shown here is the result of ﬁve independent experiments with ﬁve technical replicates in each. C, cell growth of 92.1 cells was signiﬁcantly inhibited
by induction of RGS2-HA protein expression or the Gαq inhibitor YM-254890 (10 nM). Similar to siRNA-mediated Gαq knockdown, YM-254890 treatment
caused a signiﬁcantly greater decrease in cell growth than RGS2 protein induction. In addition, the effect of RGS2 on cell growth was lost in the presence of
YM-254890. Result of three independent experiments with ﬁve technical replicates in each. *p < 0.05; ***p < 0.001; ****p < 0.0001 using two-way ANOVA
with Tukey’s post hoc test for pairwise comparisons. RGS, regulator of G protein signaling.

proliferation downstream of Gαq. First, Gαq activates phospholipase Cβ (PLCβ), which subsequently leads to activation of
protein kinase C, and downstream activation of a MAPK
cascade leading to phosphorylation of extracellular signalregulated kinase 1/2 (ERK1/2) (Figs. 4A). We therefore used
phosphorylation of ERK1/2 as a readout of signaling downstream of GαqQ209L via the canonical PLCβ pathway. First, the
MEK1/2 inhibitor trametinib (Tram) was used to determine
effects of ERK1/2 activation on 92.1 cell growth. Treatment of
92.1 cells with Tram caused complete abolishment of ERK1/2
phosphorylation (data not shown) and a corresponding strong,
dose-dependent inhibition of cell growth (Fig. S2). At low
concentrations of Tram (≤1 nM), induction of RGS2 caused
additional suppression of cell growth (Fig. 4B). This effect was
lost at higher Tram concentrations (Fig. S2). We next used
siRNA to knock down Gαq in the Dox-inducible RGS2WT
92.1 cells. Gαq siRNA caused a signiﬁcant reduction in Gαq
protein levels, as determined by Western blot (Fig. 4, C and F).
Under basal conditions, these cells displayed a high level of
ERK1/2 phosphorylation (Fig. 4, C and D). Gαq siRNA caused
a signiﬁcant decrease in ERK1/2 phosphorylation, consistent
with the model that Gαq drives proliferation in these cells via
activation of MAPK signaling (Fig. 4, C and D). Induction of
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RGS2-HA expression also caused a signiﬁcant decrease in
ERK1/2 phosphorylation (Fig. 4, C and D). However, RGS2 lost
the ability to reduce ERK1/2 phosphorylation when Gαq was
concurrently knocked down. Total ERK1/2 protein levels were
unaffected by either Dox or Gαq siRNA (Fig. 4, C and E). The
effects of RGS2-HA induction and Gαq knockdown on ERK1/2
phosphorylation could be replicated in a second GαqQ209Ldependent UM cell line, Mel-202 (Fig. 4, G–J). Importantly,
medium to high concentrations of Tram caused complete
abolishment of ERK1/2 phosphorylation (data not shown),
with virtually complete arrest in cell growth as a result
(Fig. S2). In contrast, both Dox-induced induction of RGS2
protein or Gαq siRNA only caused partial inhibition (50%–
70%) of ERK1/2 phosphorylation. Altogether these data are
consistent with the model that RGS2 mediates effects on
ERK1/2 signaling through actions that are dependent on Gαq.
RGS2 does not affect Gαq-mediated activation of YAP in UM
cells
The other main signaling pathway that connects Gαq to cell
proliferation in UM is through constitutive activation and nuclear localization of YAP/TAZ, enabling transcription of genes
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Figure 3. RGS2-mediated suppression of uveal melanoma cell growth is dependent on association with GαqQ209L. A, GαqQ209L, RGS2WT, RGS2N149A
(GAP deﬁcient), and RGS2S179D were expressed by in vitro transcription translation and subjected to co-IP, utilizing a Glu-Glu (EE) tag on Gαq. Both RGS2WT
and RGS2N149A associated with GαqQ209L, while RGS2S179D did not. Representative Western blot (B) and quantiﬁcation of six independent experiments (C)
demonstrating induction of RGS2WT-HA, RGS2N149A-HA, and RGS2S179D-HA protein expression after treatment with 1 μg/ml Dox in stably transduced
92.1 cells. RGS2S179D expressed at signiﬁcantly higher levels than RGS2WT or RGS2N149A. D, in the same experiments, induction of RGS2-HA protein
expression did not affect protein expression levels of Gαq. ***p < 0.001 using one-way ANOVA with Tukey’s post hoc test for pairwise comparisons. Cell
growth of 92.1 cells was inhibited by induction of RGS2WT (D) and RGS2N149A (E), but not by RGS2S179D (F), despite this mutant displaying higher protein
levels. Data were normalized against cell growth in the absence of Dox. Result of three independent experiments with ﬁve technical replicates in each. Cell
growth after induction of RGS2-HA was compared with growth in the absence of Dox (*) and the growth in the vector control cell line in the presence of
Dox (#). ****/####p < 0.0001 using two-way ANOVA analysis with Tukey’s post hoc test for pairwise comparisons. Dox, doxycycline; RGS, regulator of G protein
signaling.

that promote cell growth (7, 10, 23, 32). This signaling is independent of PLCβ and the canonical Hippo pathway and mediated instead through a Trio-Rho/Rac signaling mechanism (7)
(Figs. 5A and 6A). We therefore next aimed to determine the
effects of RGS2 on GαqQ209L-mediated YAP/TAZ activation in

Gq-dependent UM cell lines. First, we measured nuclear YAP/
TAZ localization in 92.1 cells, using ﬂuorescence microscopy.
We observed that YAP/TAZ were constitutively nuclear even at
densities with high cell–cell contact which would normally drive
YAP/TAZ out of the nucleus, in nontransformed, primary cells
J. Biol. Chem. (2022) 298(6) 101955
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Figure 4. RGS2 inhibits Gαq-mediated ERK1/2 phosphorylation in uveal melanoma cells. A, schematic describing the signaling pathway leading to
ERK1/2 phosphorylation downstream of Gαq. B, the MEK1/2 inhibitor trametinib (Tram) inhibits 92.1 cell growth. Induction of RGS2-HA with Dox enhances
the effect of Tram only at low concentrations (≤1 nM; and see Fig. S2). Result of three independent experiments with ﬁve technical replicates in each.
****p < 0.0001 using two-way ANOVA with Tukey’s post hoc test for pairwise comparisons. Representative Western blot (C) and quantiﬁcation of ﬁve
independent experiments (D) demonstrating that both RGS2-HA induction and siRNA-mediated Gαq knockdown results in signiﬁcantly reduced levels of
ERK1/2 phosphorylation in 92.1 cells. E, protein levels of total ERK1/2 are unaffected by either Dox or Gαq siRNA. F, efﬁciency of siRNA-mediated Gαq
knockdown in 92.1 cells was 70%. Representative Western blot (G) and quantiﬁcation of three independent experiments (H) demonstrating that both
RGS2-HA induction and siRNA-mediated Gαq knockdown results in signiﬁcantly reduced levels of ERK1/2 phosphorylation in Mel-202 cells. I, protein levels
of total ERK1/2 are unaffected by either Dox or Gαq siRNA. J, efﬁciency of siRNA-mediated Gαq knockdown in Mel-202 cells was 90%. The effect of RGS2 on
ERK1/2 phosphorylation is lost when Gαq was concurrently knocked down in both 92.1 and Mel-202 cells. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001
using one-way ANOVA with Tukey’s post hoc test for pairwise comparisons. Dox, doxycycline; ERK1/2, extracellular signal-regulated kinase 1/2; RGS,
regulator of G protein signaling.

(33, 34) (Fig. 5, B and C). Once restricted to the cytosol, YAP/
TAZ are constitutively degraded (35), resulting in a decrease in
ﬂuorescence in our assay system. Consistent with previous observations (10), siRNA-mediated knockdown of Gαq reduced
nuclear YAP/TAZ localization as measured by a reduction in
ﬂuorescence signal (Fig. 5, B and C). However, in contrast to
what was observed in our ERK1/2 phosphorylation experiments, Dox-induced expression of RGS2 had no effect on YAP/
TAZ nuclear localization (Fig. 5, B and C). This lack of effect was
independent of whether Gαq was knocked down with siRNA
(Fig. 5, B and C).
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As a direct measure of YAP/TAZ activity, we next used a
TEAD luciferase reporter in both 92.1 and Mel-202 cells, as a
measure of YAP/TAZ transcriptional activity. At baseline,
both UM cell lines showed high levels of TEAD luciferase
activity, and siRNA-mediated Gαq knockdown signiﬁcantly
reduced luciferase signal in both cell lines (Fig. 5, D and E).
Again, induction of RGS2-HA had no effect on TEAD luciferase signal, regardless of whether Gαq was knocked down or
not (Fig. 5, D and E), providing further support that RGS2
cannot inhibit YAP/TAZ signaling downstream of Gαq in
these UM cell lines.

RGS2 inhibits UM cell growfth

Figure 5. RGS2 does not affect Gαq-mediated YAP activation in uveal melanoma cells. A, schematic describing the signaling pathway leading to YAP
activation downstream of Gαq. Representative images (B) and quantiﬁcation (C) of three independent experiments demonstrating effects of Gαq siRNA and
Dox-induced RGS2 expression on nuclear localization of YAP/TAZ. Gαq siRNA results in almost a 50% reduction in YAP/TAZ nuclear localization. Induction of
RGS2 protein expression has no effect on YAP/TAZ nuclear localization. YAP/TAZ activation was measured using a lentiviral TEAD luciferase reporter in 92.1
(D) and Mel-202 (E) cells. In both cell lines, Gαq siRNA results in a signiﬁcant (75%) reduction in TEAD luciferase activity. Induction of RGS2-HA has no effect
on TEAD luciferase. Results of three independent experiments in both 92.1 and Mel-202 cells. **p < 0.01; ****p < 0.0001 using one-way ANOVA with Tukey’s
post hoc test for pairwise comparisons. Dox, doxycycline; RGS, regulator of G protein signaling; YAP, yes-associated protein 1.

Altogether, our data indicate that RGS2 can partially
suppress GαqQ209L-dependent UM cell growth, through
an effector antagonism mechanism (Fig. 6). Gαq promotes UM cell growth through two main signaling
pathways; however, RGS2 can only suppress the MAPK
kinase cascade, while leaving the YAP/TAZ signaling
unaffected.

Discussion
RGS proteins have emerged in recent years as key regulators
of G protein–mediated signaling, through both their canonical
GAP activity, as well as GAP-independent mechanisms. RGS2
is unique in its selectivity for Gαq over other Gα subtypes. This
selectivity applies not only to GAP activity but also in its
previously identiﬁed role as an effector antagonist (22). In the

Figure 6. Model for RGS2 effects on Gαq-dependent uveal melanoma cell growth. A, GαqQ209L drives 92.1 uveal melanoma cell growth through
activation of both YAP/TAZ and ERK1/2. B, RGS2 inhibits 92.1 uveal melanoma cell growth by binding GαqQ209L and acting as an effector antagonist for
ERK1/2 activation only, while leaving YAP/TAZ activation unaffected. This results in only partial inhibition of GαqQ209L induced cell growth. ERK1/2,
extracellular signal-regulated kinase 1/2; RGS, regulator of G protein signaling; YAP, yes-associated protein 1.
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current study, we identiﬁed a novel role for RGS2 in suppressing GαqQ209L-mediated UM cell growth, independent of
its canonical GAP activity. This adds another layer of
complexity for the actions of RGS2 on Gq-mediated signaling
pathways.
We used both 92.1 and Mel-202 cells, which both harbor the
GαqQ209L mutation. While this is the most prevalent mutation
in UM, other mutations in both Gαq and Gα11 represent a
large fraction of UM cases. Further studies are needed to
determine the effects of RGS2 on these mutations as well.
GαqQ209P is the second most common mutation. A previous
study determined that this mutant adopts a conformation
different from that of GαqQ209L or active GαqWT, causing
altered binding to effectors, including RGS proteins (36). Thus,
further studies are warranted to determine whether RGS2 can
inhibit UM cell growth mediated by other Gαq/11 activating
mutations.
Throughout the current study, induction of RGS2 protein
expression consistently resulted in 20% reduction in UM
cell growth. This relatively small reduction was due to RGS2
only inhibiting Gq-mediated ERK1/2 phosphorylation, while
leaving YAP/TAZ activation unaffected. Complete abolishment of ERK1/2 phosphorylation induced by the clinically
used MEK1/2 inhibitor Tram, and the resulting arrest of
92.1 cell growth (Fig. S2) indicates that abolishing ERK1/2
phosphorylation is enough to completely halt 92.1 cell
growth. However, RGS2 induction, like Gαq knockdown, did
not completely abolish ERK1/2 phosphorylation (Fig. 4),
explaining the difference in cell growth responses compared
to Tram. The partial inhibition of ERK1/2 phosphorylation by
RGS2 induction is not surprising, given that RGS2 acts on
this pathway through actions on Gαq. Therefore, it is not
possible for RGS2 induction to cause a larger effect than that
of knocking down Gαq in these cells. Instead, the larger effect
of knocking down Gαq on UM cell growth can be explained
by partial inhibition of two pathways, both contributing to
UM cell growth (Fig. 6).
The clinical relevance of this relatively small effect of RGS2
is yet to be determined, as is the molecular determination of
how RGS2 interacts with Gαq to only affect the PLCβ
‘signaling arm’. In 92.1 cells, we observed constitutively nuclear YAP/TAZ even at densities with high cell–cell contact
which would normally drive YAP/TAZ out of the nucleus.
This could possibly explain why RGS2 is not able to cause
YAP/TAZ nuclear exclusion, as the modulatory effect of RGS2
on Gαq is not enough to achieve this. The relatively modest
effect we observed on UM cell growth by RGS2 may not be
detrimental. In fact, from a clinical standpoint, and as eluded
to in the Introduction, modulation, rather than abolishment of
Gαq activity, may provide a safer alternative for therapeutic
development. Indeed, decreasing Gαq/11 activity by more than
50%, as demonstrated by early gene dosage studies in mice, is
likely to be lethal (13). Thus, the 20% reduction in cell
growth observed here may be enough to have therapeutic effect. In addition, we previously determined that increasing
RGS2 protein levels as little as 2-fold is enough to have
functional effects on GPCR signaling both in vitro and in vivo
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(37, 38). Thus, modest increases in RGS2 protein function
could have substantial beneﬁcial effects also in UM driven by
constitutively active Gαq. While more studies are needed to
determine the effect of RGS2 on UM driven by mutations
other than GαqQ209L, our current study provides evidence that
RGS2 could be a promising avenue to pursue for future targeted therapies in UM.

Experimental procedures
Materials
All chemicals and reagents were purchased from Thermo
Fisher Scientiﬁc unless otherwise stated. YM-254890
(#AG-CN2-0509-MC05) was from Adipogen Life Sciences.
Tram was from Selleck Chemicals.
DNA constructs
RGS2-HA (in pcDNA3.1) was from cDNA resource center.
RGS2N149A and RGS2S179D were created from the RGS2-HA
(in pcDNA3.1) construct using QuikChange II site-directed
mutagenesis (Agilent Technologies) according to the manufacturer’s instructions. Each was cloned into pF3K WG
(BYDV) Flexi (Promega), and pLVX-TetOne-Puro (Clontech/
Takara Bio), respectively. pLVX-TetOne-Puro and related
materials were kindly provided by Dr Michael Wendt, Purdue
University. GNAQ (in pcDNA3.1) was from cDNA resource
center. GNAQQ209L was created from GNAQ using QuikChange II site-directed mutagenesis. Each was cloned into
pF3K WG (BYDV) Flexi. The Primer sequences for construct
generation and mutagenesis are available by request.
Antibodies
Rabbit anti-HA (H6908), mouse anti-β-Actin (A2228), and
rabbit anti-β-Actin (A2066) were from Millipore Sigma.
Mouse anti-Gαq (sc-136181) was from Santa Cruz. Mouse
anti-Glu-Glu tag (901801) was from Biolegend. Mouse antipERK (9106S), rabbit anti-ERK1/2 (4695S), and rabbit antiYAP/TAZ (D24E4) were from Cell Signaling. Western blot
secondary IRDye 800CW and 680RD antibodies were all from
Li-Cor Biosciences. Immunocytochemistry secondary antibody
goat anti-rabbit, Alexa ﬂour 488 (A-11008) was purchased
from Invitrogen.
Cell culture
Cells were maintained in a humidiﬁed incubator at 37  C
with 5% CO2. Human UM 92.1 cells (Millipore Sigma,
#13012458) and Mel-202 cells (Millipore Sigma, #13012457)
were grown in Roswell Park Memorial Institute 1640 medium
(RPMI 1640; Gibco, #11875-093), supplemented with 10% fetal
bovine serum (Gibco, #16000), 100 U/ml penicillin/100 μg/ml
streptomycin (Gibco, #15140). Human embryonic kidney 293T
(HEK-293T) cells and MCF-7 breast cancer cells (ATCC,
#HTB-22) were grown in Dulbecco’s modiﬁed Eagle’s medium
(Gibco, #11995), supplemented with 10% fetal bovine serum,
100 U/ml penicillin/100 μg/ml streptomycin.
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Stable cell line development
WT

Lentiviral particles containing either RGS2 -HA,
RGS2N149A-HA, or RGS2S179D-HA (in pLVX-TetOne-Puro)
were produced in HEK-293T cells and used to transduce
92.1, Mel-202 and MCF-7 cells. Stable integration was selected
using 1 μg/ml puromycin (Fisher Scientiﬁc) for 2 weeks. The
stable cell lines were induced with Dox (Fisher Scientiﬁc) at
1 μg/ml for 24 to 72 h (as indicated in ﬁgure legends), and
successful induction of RGS2 protein expression was detected
by Western blot as described below.
siRNA transfections
siRNA transfection was performed under reduced serum
conditions (Opti-MEM) 24 h prior to transfections at 40% to
60% conﬂuency. Cells were transfected with siGENOME
SMART-POOL siRNA (Gq, M-008562-00-0005 and nontargeting, D-001206-13-05) from Dharmacon using Lipofectamine RNAiMAX (Thermo Fisher/Invitrogen). Sequences for
each siRNA is described in Table S1. Western blot was performed to detect knockdown efﬁciency.
Preparation of cell lysates
Cells were harvested on ice in lysis buffer containing protease inhibitors (20 mM Tris-HCl (pH 7.4), 150 mM NaCl,
1 mM EDTA, 1 mM β-glycerophosphate, 1% Triton X-100,
0.1% SDS, and cOmplete Protease Inhibitor Cocktail EDTAfree [Roche]). Lysates were sonicated for 10 min at 4  C,
centrifuged at 14,800 rpm for 10 min, and the supernatants
were used for SDS-PAGE and Western blot. Total protein
concentration was determined using the Pierce BCA Protein
Assay Kit (Thermo Scientiﬁc).
In vitro transcription/translation and co-IP
TnT SP6 High-Yield Wheat Germ Protein Expression System kit (L3260; Promega) was used as directed by the manufacturer. The transcription/translation reaction was performed
using 2 μg DNA (RGS2 or GNAQ in pF3K WG (BYDV) Flexi)
for 2 h at room temperature. Translated proteins were mixed
and allowed to form complexes for 1 h at room temperature
with gentle rotation in RIPA buffer (50 mM Tris-HCl [pH 7.4],
150 mM NaCl, 0.25% w/v Deoxycholate, 1 mM EDTA, 1% NP40, complete Protease Inhibitor Cocktail EDTA-free). 30 μl
was removed saved as input. 2 μl mouse anti-Glu-Glu antibody
was added, and co-IP was allowed to proceed for 16 to 18 h at
4  C with gentle rotation. 20 μl Protein G agarose beads
(Roche) was added, followed by 2 h incubation at 4  C with
gentle rotation. Samples were washed three times with RIPA
buffer and once with phosphate buffered saline. Bound proteins were eluted at 95  C in 30 μl SDS sample buffer (Li-Cor
Biosciences).
SDS-PAGE and Western blot
Equal amounts of protein in each lane were resolved on a
10% to 12% SDS-PAGE gel for 1 h at 160 V. Samples were
transferred to an Immobilon-FL PVDF membrane (Millipore)

and subjected to Western immunoblot analysis using Li-Cor
blocking buffer for both blocking and antibody diluents.
Membranes were blocked for 1 h, then incubated 16 to 18 h in
primary antibodies, and 1 h with IRDye secondary antibodies.
Following each antibody incubation, membranes were washed
four times in phosphate buffered saline with 0.1% Tween-20.
Membranes were imaged using a Li-Cor Odyssey CLx
imager (Li-Cor Biosciences).
Real-time Glo cell growth assay
Real-time Glo MT Cell Viability Assay Kit (G9711, Promega) was used as instructed. For cell growth assay detected in
real-time, cells were plated at low density (50–150 cells/well)
in 20 μl complete culture media, in a white 384-well plate
(CulturPlate-384, #6007680, PerkinElmer). 20 μl 2× MT
substrate and NanoLuc enzyme with or without Dox (ﬁnal
concentration 1 μg/ml) was added, and plates were centrifuged at 1000 rpm for 1 min to collect cells and reagents at
the bottom of each well. Plates were incubated at 37  C and
luminescence was detected at 1 h (baseline), 24 h, 48 h, and
72 h on a Synergy Neo2 plate reader (BioTek) using the same
gain (continuous protocol with reads from the same well at
every time point). For 6-days cell growth assays (end-point
protocol), cells were plated at equal cell densities (5000–10,000 cells/well) in a 24-well plate in 500 μl complete culture
media. On the second day, cells were collected (baseline, day
0), diluted 20× in culture media, and re-plated in 20 μl
complete culture media in a white 384-well plate. 20 μl 2×
MT substrate and NanoLuc enzyme were added, followed by
1 h incubation at 37  C, and luminescence detected using a
Synergy Neo2 plate reader. This procedure was repeated on
day 2, 4, and 6. Fresh Dox was added ever 48 h to maintain
RGS2-HA expression.
Immunoﬂuorescence imaging
Cells were plated into tissue culture treated 96-well plates
and allowed to attach for 6 h siRNA transfection and Dox
treatment was carried out as described above. Cells were ﬁxed
in 4% paraformaldehyde, permeabilized with 0.25% Triton
X-100, blocked with 1% bovine serum albumin, and incubated
with YAP/TAZ primary antibody 1:200 overnight at 4  C, and
anti-rabbit secondary antibody 1:1000 for 1 h at room temperature, cells were imaged, and YAP/TAZ nuclear localization was quantiﬁed as previously described (39–41) using a
Cytation5 (Biotek). Brieﬂy, cell nuclei were identiﬁed using the
DAPI channel and mean YAP/TAZ nuclear intensity was
determined for the control siRNA, Dox group. A threshold
value of 85% of this intensity was then used to quantify the
percentage of YAP/TAZ nuclear positive cells after treatments.
In initial experiments developing this image analysis protocol,
we compared the automated software analysis to two different
investigators asked to identify nuclear positive YAP/TAZ cell
populations, blinded to the conditions. The automated analysis
was within 5% variance of the two investigators, for each
condition.
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Luciferase reporter assay
Cells were plated at 50% to 60% density and incubated at
37  C overnight. Cells were transfected with siRNA using the
protocol described above. After 4 h, Opti-MEM was replaced
with normal cell culture medium, containing TEAD-Luc lentivirus particles (#79833, BPS Bioscience), 5 μg/ml Polybrene
(#sc-134220, Santa Cruz Biotechnology), and 1 μg/ml Dox.
Transduction was allowed to proceed at 37  C for 16 to 18 h.
2000 cells were re-plated in a 384 well plate using serum-free
medium. Gly-Phe-7-Amino-4-triﬂuoromethylcoumarin (GFAFC) viability substrate (MP Biomedicals) was diluted 1:1000 in
serum-free medium, and 5 μl was added to each well. Plates
were incubated at 37  C for 30 min, then ﬂuorescence was
detected on a Synergy Neo2 multimode plate reader (BioTek).
15ul luciferase substrate assay solution (E2610, Promega) was
added, followed by 5 min incubation at room temp and
detection of luminescence on a Synergy Neo2 plate reader.
Statistical analysis
Western blot images were captured and quantiﬁed using
Image Studio software (Li-Cor Biosciences). For western blots,
band intensity for proteins were normalized against a loading
control. pERK1/2 was normalized against total ERK1/2. All data
were analyzed using GraphPad Prism 9.0 (GraphPad). Datasets
with two groups were analyzed using Student’s unpaired t test.
Datasets with three or more groups were analyzed with one-way
or two-way ANOVA, depending on the nature of the groups as
indicated in each ﬁgure. Groups were compared with Tukey’s
post hoc test for multiple comparisons. All experiments were
run at least three times. Data are presented as mean ± SEM with
a p-value less than 0.05 considered signiﬁcant.

Data availability
All available data are contained within this manuscript.
Sequences for primers, siRNA, and constructs are available
upon request. DNA constructs are available upon request.
These should be made to jsjogren@purdue.edu.
Supporting information—This
information.
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